BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 14.3//EN BEGIN:VTIMEZONE TZID:Arab Standard Time BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:Arab Standard Time TZOFFSETFROM:+0300 TZOFFSETTO:+0300 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Abstract:Big cancer \ngenomics data have been accumulated at a fascinating speed. But it \nremains a great challenge to translate these b ig data into biomedical \ninsights\, thereby making translational impacts. To address this \nchallenge\, I will discuss (i) how to develop AI-driven data analytics to\n enable a broad community to analyze these data in a m ore fluent way\; \n(ii) how to characterize the molecular basis of human c ancers in a more \ncomprehensive way\; and (iii) how to develop functional genomics \napproaches to identify key events for clinical applications.&n bsp\;Bio:Dr.\n Liang is a Barnhart Family Distinguished Professor in Targe ted \nTherapies and the Deputy Chair of Department of Bioinformatics and \ nComputational Biology at the University of Texas MD Anderson Cancer \nCen ter. He is also a professor in the Department of Systems Biology. He \nrec eived his B.S. in chemistry from Peking University (China) in 2001 \nand P h.D. in quantitative and computational biology from Princeton \nUniversity (NJ\, USA) in 2006. Dr. Liang then finished his postdoctoral \ntraining i n evolutionary and computational genomics at the University of\n Chicago. He joined MD Anderson Cancer Center as Assistant Professor and\n started h is own group in 2009. At MD\n Anderson\, Dr. Liang's group focuses on bioi nformatics tool development\,\n integrated cancer genomic analysis\, regul atory RNA \nregulation/modification\, and cancer systems biology. His syst ematic \nstudies on enhancer regulation\, RNA editing\, functional proteom ics\, sex \neffects\, and driver mutations in cancer have generated profou nd impacts \non the biomedical research community and attracted wide atten tion such \nas The Wall Street Journal and Newsweek. The bioinformatics to ols his \ngroup developed (such as TCPA\, TANRIC\, FASMIC\, DrBioRight) co llectively \nhave >\;110\,000 active users worldwide. Since 2010\, he ha s published \n>\;140 papers \; total citation >\;25\,000 times)\, including 41 \ncorresponding-author papers in top journals such as Cell\, Cancer Cell\, \nNature Genetics\, Nature Biotechnology\, and Nature Method s.Dr.\n Liang have taken leadership roles in large cancer consortium proje cts\, \nincluding chair of The Cancer Genome Atlas (TCGA) PanCanAtlas work ing \ngroups\, one co-leader of International Cancer Genome Consortium (IC GC) \nPan-Cancer Whole Genome Analysis Project\, and one co-chair of NCI \ nGenomic Data Commons (GDC) QC working group. He won several awards \nincl uding MD Anderson R. Lee Clark Fellow Award (2014)\, the University \nof T exas System STARS Award (2015)\, MD Anderson Faculty Scholar Award \n(2018 )\, and AACR Team Science Award (2020). He is an elected Fellow of \nAmeri can Association for the Advancement of Science (AAAS). DTEND:20230321T140000Z DTSTAMP:20240329T052146Z DTSTART:20230321T130000Z LOCATION:Building 2 - Level 5 - Room 5209 SEQUENCE:0 SUMMARY:AI\, Big data and Cancer Systems UID:RFCALITEM638472973065361085 X-ALT-DESC;FMTTYPE=text/html:
Abstract:
Big cancer \n
genomics data have been accumulated at a fascinating speed. But it \nremai
ns a great challenge to translate these big data into biomedical \ninsight
s\, thereby making translational impacts. To address this \nchallenge\, I
will discuss (i) how to develop AI-driven data analytics to\n enable a bro
ad community to analyze these data in a more fluent way\; \n(ii) how to ch
aracterize the molecular basis of human cancers in a more \ncomprehensive
way\; and (iii) how to develop functional genomics \napproaches to identif
y key events for clinical applications. \;
Bio:
Dr.\n Liang is a Barnhart Family Distinguished Professor in Targeted \
nTherapies and the Deputy Chair of Department of Bioinformatics and \nComp
utational Biology at the University of Texas MD Anderson Cancer \nCenter.
He is also a professor in the Department of Systems Biology. He \nreceived
his B.S. in chemistry from Peking University (China) in 2001 \nand Ph.D.
in quantitative and computational biology from Princeton \nUniversity (NJ\
, USA) in 2006. Dr. Liang then finished his postdoctoral \ntraining in evo
lutionary and computational genomics at the University of\n Chicago. He jo
ined MD Anderson Cancer Center as Assistant Professor and\n started his ow
n group in 2009.
At MD\n Anderson\, Dr. Liang's group focuses on bi oinformatics tool development\,\n integrated cancer genomic analysis\, reg ulatory RNA \nregulation/modification\, and cancer systems biology. His sy stematic \nstudies on enhancer regulation\, RNA editing\, functional prote omics\, sex \neffects\, and driver mutations in cancer have generated prof ound impacts \non the biomedical research community and attracted wide att ention such \nas The Wall Street Journal and Newsweek. The bioinformatics tools his \ngroup developed (such as TCPA\, TANRIC\, FASMIC\, DrBioRight) collectively \nhave >\;110\,000 active users worldwide. Since 2010\, he has published \n>\;140 papers \; total citation >\;25\,000 times)\ , including 41 \ncorresponding-author papers in top journals such as Cell\ , Cancer Cell\, \nNature Genetics\, Nature Biotechnology\, and Nature Meth ods.
Dr.\n Liang have taken leadership roles in large cancer consort
ium projects\, \nincluding chair of The Cancer Genome Atlas (TCGA) PanCanA
tlas working \ngroups\, one co-leader of International Cancer Genome Conso
rtium (ICGC) \nPan-Cancer Whole Genome Analysis Project\, and one co-chair
of NCI \nGenomic Data Commons (GDC) QC working group. He won several awar
ds \nincluding MD Anderson R. Lee Clark Fellow Award (2014)\, the Universi
ty \nof Texas System STARS Award (2015)\, MD Anderson Faculty Scholar Awar
d \n(2018)\, and AACR Team Science Award (2020). He is an elected Fellow o
f \nAmerican Association for the Advancement of Science (AAAS).